Biopharmas

Predictive Protein Biomarker-based Treatment
Decision Support

Pathway-based assessement of the activated proteome using Reverse Phase Protein Array (RPPA) and laser caption microdissection (LCM) to support therapeutic development in oncology and immuno-oncology from discovery through clinical trials.

Patented Technology Offering:

Coverage

~600 proteins/phosphoproteins across key canonical pathways

Quantification

RPPA enables detection of up to 500X dynamic range¹

Translatability

Homogenous assay from research to clinic

Sensitivity

Can detect 100 analytes from just 10,000 cells per experiment

Customization

Ability to quickly add your targets and accept multiple sample inputs (tissues (FFPE/frozen) and cells)

Predictivity

Proteomic biomarkers are more predictive than genomics²